Cocrystal Pharma, Inc.
COCP
$1.31
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 26.84% | -18.58% | -28.25% | 23.76% | 0.82% |
| Total Depreciation and Amortization | -30.00% | -169.09% | 22.77% | 18.45% | 138.83% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -41.18% | 54.48% | -11.67% | -46.38% | -50.16% |
| Change in Net Operating Assets | -101.27% | -137.06% | 188.21% | -145.69% | 258.56% |
| Cash from Operations | 4.99% | -91.09% | 33.33% | -44.74% | 32.03% |
| Capital Expenditure | 100.00% | -- | 100.00% | 82.22% | -391.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | -- | 100.00% | 82.22% | -391.67% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 100.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | 100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6.65% | -91.09% | -136.81% | -42.62% | 31.78% |